<--- Back to Details
First PageDocument Content
Clinical research / FDA Fast Track Development Program / Center for Drug Evaluation and Research / Title 21 of the Code of Federal Regulations / Surrogate endpoint / Criticism of the Food and Drug Administration / New Drug Application / Medicine / Food and Drug Administration / Health
Clinical research
FDA Fast Track Development Program
Center for Drug Evaluation and Research
Title 21 of the Code of Federal Regulations
Surrogate endpoint
Criticism of the Food and Drug Administration
New Drug Application
Medicine
Food and Drug Administration
Health

Microsoft Word - 10331dft.doc

Add to Reading List

Source URL: www.fda.gov.

Download Document from Source Website

File Size: 169,14 KB

Share Document on Facebook

Similar Documents

The EVMS Autism Spectrum Disorder Program was started by Maria Urbano, M.D., and Kathrin Hartmann, Ph.D., in 2010 to provide clinical services, research, and community outreach to individuals and their families for Autis

DocID: 1vrwY - View Document

Towards a Composite Clinical Endpoint: Identifying a Core Set of Patient and Caregiver Relevant Outcome Measures Through Qualitative Research on the Global Impact of Dravet Syndrome Rima Nabbout1, Stephane Auvin2, Cather

DocID: 1vpIt - View Document

Clinical Research Registration at Public Registry

DocID: 1vnxr - View Document

Grattoni Alessandro, Ph.D. Chairman, The Department of Nanomedicine, The Houston Methodist Research Institute, Houston, Texas (USA) Dr. Grattoni’s research is dedicated to the development and clinical translation of im

DocID: 1vi9N - View Document

Clinical & Translational Research 101 Thursday, August 10, 2017 Time Location

DocID: 1vglz - View Document